KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) EBIT (2016 - 2025)

Alnylam Pharmaceuticals' EBIT history spans 16 years, with the latest figure at $131.7 million for Q4 2025.

  • For Q4 2025, EBIT rose 225.26% year-over-year to $131.7 million; the TTM value through Dec 2025 reached $501.6 million, up 383.56%, while the annual FY2025 figure was $501.6 million, 383.56% up from the prior year.
  • EBIT reached $131.7 million in Q4 2025 per ALNY's latest filing, down from $368.0 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $368.0 million in Q3 2025 to a low of -$258.0 million in Q3 2022.
  • Average EBIT over 5 years is -$72.6 million, with a median of -$131.3 million recorded in 2021.
  • Peak YoY movement for EBIT: tumbled 135.96% in 2024, then surged 578.49% in 2025.
  • A 5-year view of EBIT shows it stood at -$194.6 million in 2021, then rose by 3.06% to -$188.6 million in 2022, then soared by 38.28% to -$116.4 million in 2023, then increased by 9.66% to -$105.2 million in 2024, then surged by 225.26% to $131.7 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's EBIT are $131.7 million (Q4 2025), $368.0 million (Q3 2025), and -$16.2 million (Q2 2025).